Posted inInfectious Diseases news
Cefazolin Is Non‑Inferior to Cloxacillin for MSSA Bacteraemia and Causes Less Kidney Injury: The CloCeBa Randomised Trial
The CloCeBa trial found cefazolin non‑inferior to cloxacillin for meticillin‑susceptible Staphylococcus aureus (MSSA) bacteraemia, with similar 90‑day composite outcomes and substantially lower rates of serious adverse events and acute kidney injury.
